Analyst Ratings For NASDAQ:ONCE – Spark Therapeutics (NASDAQ:ONCE)
Today, Raymond James reiterated its Buy rating on NASDAQ:ONCE – Spark Therapeutics (NASDAQ:ONCE).
Some recent analyst ratings include
- 5/23/2018-Raymond James Reiterated Rating of Buy.
- 5/9/2018-Wedbush Reiterated Rating of Underperform.
- 5/9/2018-Barclays Reiterated Rating of Positive ➝ Overweight.
- On 4/20/2018 John Furey, COO, sold 6,723 with an average share price of $82.50 per share and the total transaction amounting to $554,647.50.
- On 4/18/2018 John Furey, COO, sold 13,277 with an average share price of $82.52 per share and the total transaction amounting to $1,095,618.04.
- On 4/12/2018 John Furey, COO, sold 20,000 with an average share price of $77.51 per share and the total transaction amounting to $1,550,200.00.
- On 12/11/2017 John Furey, COO, sold 18 with an average share price of $46.33 per share and the total transaction amounting to $833.94.
- On 12/8/2017 John Furey, COO, bought 18 with an average share price of $73.48 per share and the total transaction amounting to $1,322.64.
- On 11/28/2017 Katherine A High, Insider, sold 5,000 with an average share price of $71.32 per share and the total transaction amounting to $356,600.00.
- On 11/16/2017 Stephen W Webster, CFO, sold 10,000 with an average share price of $70.14 per share and the total transaction amounting to $701,400.00.
Recent Trading Activity for NASDAQ:ONCE – Spark Therapeutics (NASDAQ:ONCE)
Shares of NASDAQ:ONCE – Spark Therapeutics closed the previous trading session at 76.93 up +2.10 2.81% with shares trading hands.